Expression profile analysis of hippocampal CA1 pyramidal neurons in aged Ts65Dn mice, a model of Down syndrome (DS) and Alzheimer's disease (AD)

被引:31
作者
Alldred, Melissa J. [1 ,2 ]
Lee, Sang Han [3 ]
Petkova, Eva [4 ,5 ]
Ginsberg, Stephen D. [1 ,2 ,6 ]
机构
[1] Nathan S Kline Inst Psychiat Res, Ctr Dementia Res, Orangeburg, NY 10962 USA
[2] NYU, Langone Med Ctr, Dept Psychiat, New York, NY USA
[3] Nathan S Kline Inst Psychiat Res, Div Med Phys, Orangeburg, NY 10962 USA
[4] Nathan S Kline Inst Psychiat Res, Div Child Psychiat, Orangeburg, NY 10962 USA
[5] NYU, Langone Med Ctr, Dept Child & Adolescent Psychiat, New York, NY USA
[6] NYU, Langone Med Ctr, Dept Physiol & Neurosci, New York, NY USA
关键词
Alzheimer's disease; BDNF; Down syndrome; Glutamatergic neurotransmission; Hippocampus; Laser capture microdissection; Murine model; Neurotrophin; SYNDROME MOUSE MODEL; MILD COGNITIVE IMPAIRMENT; CHOLINERGIC BASAL FOREBRAIN; FIMBRIA-FORNIX TRANSECTION; AMYLOID PRECURSOR PROTEIN; TC RNA AMPLIFICATION; FACTOR GENE-THERAPY; NERVE GROWTH-FACTOR; TERMINAL CONTINUATION; NMDA RECEPTORS;
D O I
10.1007/s00429-014-0839-0
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
Down syndrome (DS) is caused by the triplication of human chromosome 21 (HSA21) and is the most common genetic cause of intellectual disability, with individuals having deficits in cognitive function including hippocampal learning and memory and neurodegeneration of cholinergic basal forebrain neurons, a pathological hallmark of Alzheimer's disease (AD). To date, the molecular underpinnings driving this pathology have not been elucidated. The Ts65Dn mouse is a segmental trisomy model of DS and like DS/AD pathology, displays age-related cognitive dysfunction and basal forebrain cholinergic neuron (BFCN) degeneration. To determine molecular and cellular changes important for elucidating mechanisms of neurodegeneration in DS/AD pathology, expression profiling studies were performed. Molecular fingerprinting of homogeneous populations of Cornu Ammonis 1 (CA1) pyramidal neurons was performed via laser capture microdissection followed by Terminal Continuation RNA amplification combined with custom-designed microarray analysis and subsequent validation of individual transcripts by qPCR and protein analysis via immunoblotting. Significant alterations were observed within CA1 pyramidal neurons of aged Ts65Dn mice compared to normal disomic (2N) littermates, notably in excitatory and inhibitory neurotransmission receptor families and neurotrophins, including brain-derived neurotrophic factor as well as several cognate neurotrophin receptors. Examining gene and protein expression levels after the onset of BFCN degeneration elucidated transcriptional and translational changes in neurons within a vulnerable circuit that may cause the AD-like pathology seen in DS as these individuals age, and provide rational targets for therapeutic interventions.
引用
收藏
页码:2983 / 2996
页数:14
相关论文
共 98 条
[1]   Ts65Dn - localization of the translocation breakpoint and trisomic gene content in a mouse model for Down syndrome [J].
Akeson, EC ;
Lambert, JP ;
Narayanswami, S ;
Gardiner, K ;
Bechtel, LJ ;
Davisson, MT .
CYTOGENETICS AND CELL GENETICS, 2001, 93 (3-4) :270-276
[2]   Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction [J].
Alldred, Melissa J. ;
Duff, Karen E. ;
Ginsberg, Stephen D. .
NEUROBIOLOGY OF DISEASE, 2012, 45 (02) :751-762
[3]   Terminal Continuation (TC) RNA Amplification Enables Expression Profiling Using Minute RNA Input Obtained from Mouse Brain [J].
Alldred, Melissa J. ;
Che, Shaoli ;
Ginsberg, Stephen D. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2008, 9 (11) :2091-2104
[4]   Terminal continuation (TC) RNA amplification without second strand synthesis [J].
Alldred, Melissa J. ;
Che, Shaoli ;
Ginsberg, Stephen D. .
JOURNAL OF NEUROSCIENCE METHODS, 2009, 177 (02) :381-385
[5]  
Applied Biosystems, 2008, GENE EXPR, V2009, P1
[6]   The "Down Syndrome Critical Region" Is Sufficient in the Mouse Model to Confer Behavioral, Neurophysiological, and Synaptic Phenotypes Characteristic of Down Syndrome [J].
Belichenko, Nadia P. ;
Belichenko, Pavel V. ;
Kleschevnikov, Alexander M. ;
Salehi, Ahmad ;
Reeves, Roger H. ;
Mobley, William C. .
JOURNAL OF NEUROSCIENCE, 2009, 29 (18) :5938-5948
[7]   Synaptic structural abnormalities in the Ts65Dn mouse model of Down syndrome [J].
Belichenko, PV ;
Masliah, E ;
Kleschevnikov, AM ;
Villar, AJ ;
Epstein, CJ ;
Salehi, A ;
Mobley, WC .
JOURNAL OF COMPARATIVE NEUROLOGY, 2004, 480 (03) :281-298
[8]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[9]   Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial [J].
Boada, R. ;
Hutaff-Lee, C. ;
Schrader, A. ;
Weitzenkamp, D. ;
Benke, T. A. ;
Goldson, E. J. ;
Costa, A. C. S. .
TRANSLATIONAL PSYCHIATRY, 2012, 2 :e141-e141
[10]   Differential preservation of AMPA receptor subunits in the hippocampi of Alzheimer's disease patients according to Braak stage [J].
Carter, TL ;
Rissman, RA ;
Mishizen-Eberz, AJ ;
Wolfe, BB ;
Hamilton, RL ;
Gandy, S ;
Armstrong, DM .
EXPERIMENTAL NEUROLOGY, 2004, 187 (02) :299-309